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Abstract  
3D printed microneedle arrays were fabricated using a biocompatible resin through 
stereolithography (SLA) for transdermal insulin delivery. Microneedles were built by 
polymerising consecutive layers of a photopolymer resin. Thin layers of insulin and sugar 
alcohol or disaccharide carriers were formed on the needle surface by inkjet printing. The 
optimization of the printing process resulted in superior skin penetration capacity of the 
3D printed microneedles compared to metal arrays with minimum applied forces varying 
within the range of 2 to 5N. Micro–CT analysis showed strong adhesion of the coated films 
on the microneedle surface even after penetration to the skin. In vivo animal trials revealed 
fast insulin action with excellent hypoglycaemia control and lower glucose levels achieved 
within 60 min, combined with steady state plasma glucose over 4 h compared to 
subcutaneous injections.  
 
Introduction 
Transdermal Drug Delivery (TDD), the ability to effectively convey drugs through the human 
skin, is an appealing concept, aiming at surpassing the pitfalls of the traditional administration 
routes. The broader adoption of the transdermal route, however, is hampered by restrictions that 
stem from the nature of the skin barrier itself, especially by the stratum corneum. Microneedles 
(MNs) are small devices that can pierce this outermost, most impermeable layer of the human 
skin and successfully deliver active substances such as drugs, Ribonucleic acid (RNA), 
Deoxyribonucleic acid (DNA), and vaccines straight into the dermal microcirculation [1–4] . 
Due to their small size they leave skin nerves intact upon insertion [5], while they increase 
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bioavailability since the drug does not pass through any metabolic systems [6]. The MN-
mediated drug delivery is realised through multiple strategies that employ solid, coated, hollow, 
hydrogel-forming and soluble MNs [7]. 
Since their introduction over 20 years ago, MN systems have attracted significant attention for 
their potential to replace traditional drug administration routes. In the field of diabetes type 1 and 
some types of type 2, the vast majority of patients rely on subcutaneous needle injections for 
insulin replacement, a treatment approach highly associated with reduced patient-compliance [8]. 
Pain, skin thickening due to recurring injections, needle phobia and insulin leakages on the skin 
surface [9,10] have motivated vigorous research on MN-based systems for transdermal insulin 
delivery. 
Recent advances encompass the use of moulding techniques for the development of insulin-
loaded dissolvable MN systems. Wang et al. introduced a bioinspired MN system consisting of 
dissolvable cross-linked poly(vinyl alcohol) (PVA) gel, catalase and glucose oxidase (GOx) that 
responds to high glucose conditions by releasing insulin to the circulation. In vivo tests showed 
that the systems were effective in maintaining normal blood glucose levels [11]. In another 
study, modified alginate and hyaluronate were combined into a dissolvable, insulin-
encapsulating MN system. The MN arrays demonstrated good mechanical properties and skin 
penetration capability while clinical studies demonstrated that the MNs almost fully dissolved 
into the skin. The released insulin achieved a sustained hypoglycaemic effect and good relative 
bioavailability of insulin, compared with subcutaneous injections [12]. Similar results in terms of 
mechanical properties, relative insulin bioavailability and pharmacological activity were also 
obtained by a study that manufactured composite dissolvable MNs [13]. The forenamed studies 
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demonstrate that MN can be a promising alternative to subcutaneous injections for insulin 
therapy.  
Nonetheless, there are several hampering parameters that need to be taken under consideration 
for the development of transdermal insulin delivery systems. The first relates to the time needed 
for the detection of the drug into the systemic circulation; dissolvable systems are highly 
dependent on the dissolution rate of the materials encapsulating the drug and may not be suitable 
for fast insulin administration. To circumvent that issue, Ross et al. developed a solid MNs-
based system, coated with insulin-containing formulations through inkjet printing [14]. The use 
of this technology permitted the accurate deposition of uniform and homogeneous coatings, with 
high reproducibility. The implementation of inkjet printing for the development of thin layers on 
the microneedle surface resulted in rapid insulin release within the first 20 min. 
Another pitfall stems from the use of moulding techniques, that involve a series of multiple, 
often time-consuming steps. It is evident, that the upscaling of such processes can be 
challenging. Furthermore, there is a lack of clinical data related to cytotoxicity of materials used 
for moulded microneedles which actually limits their applications. Another important 
disadvantage is the limited drug loading in polymeric microneedles without affecting their 
mechanical properties and piercing capacity. In order to circumvent this issue several authors 
proposed the use of large patches which in turn results in difficulties to apply the arrays in a 
uniform manner and subsequently in dose variation of the administrated substances.  Recently, 
efforts have been made on the integration of the revolutionary technology of 3D printing as a 
manufacturing method for MN-based systems. 3D printing or Additive Manufacturing (AM) is a 
family of technologies that implement layer-by-layer processes to fabricate physical models, 
based on a Computer Aided Design (CAD) model. 3D printing permits the fabrication of high 
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degrees of complexity with great reproducibility, in a fast and cost-effective fashion [15–18]. In 
the field of transdermal drug delivery systems, the use of photopolymerization-based techniques 
such as Stereolithography (SLA), Digital Light Processing (DLP) and Two-Photon-
Polymerization (2PP) for the development of MNs has been reported [19–22]. Gittard et al. 
fabricated MNs of various geometries for wound healing applications using a DLP system. The 
MNs were then coated with silver and zinc oxide thin films by pulse laser deposition and their 
antimicrobial character was verified [23]. In another study, drug-loaded MNs were developed 
when a skin anticancer drug was incorporated into the photo-sensitive polymer blend prior to 
photopolymerization through a micro-stereolithographic (DLP) apparatus [24]. 
In this study, 3D printed MN arrays featuring two different MN designs, pyramid and spear, 
were developed employing a commercial SLA printer and a biocompatible Class 1 polymer. The 
3D printed arrays were subsequently coated with insulin–sugar films using inkjet printing. 
Mannitol, trehalose and xylitol were used as insulin carriers to preserve insulin activity prior to 
the deposition of active films on the MNs surface. In vitro and in vivo studies demonstrated rapid 
insulin release from the coated MN systems. The usage of SLA for 3D printing of microneedle 
arrays is anticipated to overcome the existing disadvantages of conventional techniques by 
providing high precision, rapid fabrication, reduced processing steps and freedom to print a wide 
range of shapes.  
Materials and methods 
Materials 
The insulin employed in this study was bovine and was procured in a 10 mg mL
-1
 solution from 
Sigma-Aldrich (Gillingham, UK). Xylitol (Xylisorb 90) and mannitol (Pearlitol) were 
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donated by Roquette Freres (France) while trehalose dihydrate was bought from Sigma-Aldrich 
(Gillingham, UK). The resin used to fabricate the MNs was the biocompatible Class I resin, 
Dental SG, by Formlabs. Streptozocin (≥75% α-anomer basis, ≥98%) and citric acid were both 
purchased from Merck Chemical Co. (Darmstadt, Germany). All solvents were of analytical 
grades. 
 
Additive manufacturing of microneedles 
The MN arrays were designed using an engineering software (SolidWorks, Dassault Systems) as 
patches of 15x15x1 mm. The patches featured two different needle shapes, a pyramid and a flat 
spear shaped that geometrically resembled the shape of metallic MNs that has been studied 
elsewhere [16]. This design, named ‘spear’ in the framework of this study, had base dimensions 
of 0.08x1 mm, while the dimensions of the base for the pyramid MN were 1x1 mm. The length 
of all MNs was 1 mm and all patches had a 6x8 needle layout, yielding 48 MNs per patch. The 
arrays were 3D printed using the Form 2 SLA printer by Formlabs with high resolution 
capabilities (25 and 140 microns for z and x axes, respectively). After fabrication, the arrays 
were washed in isopropyl alcohol bath to remove unpolymerized resin residues and then cured 
for 60 min at 40 
o
C under UV radiation using the MeccatroniCore BB Cure Dental station. 
Coating of microneedles through inkjet printing 
An inkjet printer was employed (NanoPlotter II, Gesim, Germany) to print thin insulin-sugar 
films on the surface of the 3D printed MNs. The inkjet printer forms the drug-containing films 
depositing multiple layers of insulin – sugar droplets on each microneedle using a piezo-driven 
dispenser (PicPip 300). In each coating cycle (layer), the dispenser jetted 2 droplets of 
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formulation in 10 spots along each needle’s longitudinal axis. A total of 92 coating cycles 
resulted in a 10 UI (350 µg) of insulin per array. The coated arrays were then incubated at room 
temperature for 24 hours to allow the evaporation of the solvent (de-ionised water) and the 
formation of uniform films. For the purposes of this study three coating formulations were used, 
consisting of insulin:xylitol (5:1 wt/wt), insulin: mannitol (5:1 wt/wt) and insulin:trehalose (5:1 
wt/wt) as 2% solid content. Prior to the coating process, the arrays were mounted on a metal stub 
at 45
o
 relative to the dispenser, while its tip (50 m) was placed close to the MN surface to avoid 
losses of material. 
Scanning electron microscopy (SEM) 
The coated MN arrays were mounted onto aluminium stubs using a double-sided carbon 
adhesive tape (Agar Scientific, UK). Each coated MN array was examined by SEM (Hitachi SU 
8030, Japan) using a low accelerating voltage (1.0kV). A low accelerating voltage was used to 
avoid electrical charges on the MNs. The images of coated MNs were captured digitally from a 
fixed working distance (11.6 mm) using different magnifications (e.g. 30, 80, 110 or 120 x). 
X-Ray Computer Micro Tomography 
X-Ray Micro Computer Tomography (μCT) scans were performed on coated 3D printed 
pyramid MN. The equipment employed was a Bruker Skyscan 1172, with an SHT 11 Megapixel 
camera and a Hamamatsu 80kV (100μΑ) source. The samples comprised of 3D printed pyramid 
MN coated with the three insulin/sugar formulations; Sample A: insulin:xylitol (5:1 wt/wt), 
Sample B: insulin: mannitol (5:1 wt/wt) and Sample C: insulin:trehalose (5:1 wt/wt). After the 
scans of the coated arrays were performed, the arrays were inserted in 8-ply strips of parafilm, 
applying a force of 5 N, to examine the performance of the coating during piercing and to 
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investigate whether any coating material will remain on the parafilm surface, causing drug 
losses. Moreover, the penetration depth was measured. The samples were mounted vertically on 
a portion of dental wax and positioned 259.4 mm from the source. No filter was applied to the X-
Ray source and a voltage of 80 kV was applied for an exposure time of 1,050 ms. The images 
generated were 2,664 x 4,000 pixels with a resolution of 6.75 μm per pixel.  
A total of 962 images were taken in 0.2
o
 steps around one hemisphere of the sample with the 
average of 4 frames taken at each rotation step. The images were collected and a volumetric 
reconstruction of the sample generated by Bruker’s CTvol software. The threshold for this 
attenuation signal was set manually to eliminate speckle around the sample, and then further 
cleaned with a thresholding mask using Bruker’s CTAn software. The images produced by the 
μCT are based on the level of attenuation though the sample, which is dependent on the thickness 
of the material and its absorption coefficient. Here, it is assumed that the absorption coefficient is 
linearly proportional to the density of the material and the resulting densities expressed in 
Hounsfield Units (HU), with -1000 being the density of air and 0 being the density of water. 
Circular Dichroism (CD) 
Insulin solution and the respective solutions of the insulin-sugar films were diluted to 1.0 mg 
mL
-1
 in deionised water and the spectra were recorded at 20 ºC between 190 and 260 nm by CD 
(Chirascan, Applied Photophysics, UK) using a 0.1 mm polarization certified quartz cell 
(Hellma). Spectra were recorded using a step size of 1 nm, a bandwidth of 1 nm and an 
acquisition time of 1 sec. Four scans were recorded for each sample, averaged and a 
corresponding spectrum of water was subtracted from each spectrum. For estimation of the 
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secondary structural composition of insulin, the CD spectra were evaluated using the CD SSTR 
method [25]. 
Raman Spectroscopy 
The films and their respective components were analysed using Raman microscopy (Jobin Yvon 
LabRam I) with a laser of 532 nm wavelength coupled with an optical microscope with 50x 
objective. 
Penetration studies through porcine skin 
The effect of the MN geometry on the force required to pierce the skin has been documented 
[26]. In this study, to determine the effect of needle shape on the force required for skin 
penetration, piercing tests using porcine skin were conducted. Identical piercing tests were 
carried out using metallic MN arrays that have been studied and are described in literature [16], 
to maintain a frame of reference with the respective studies. A texture analyser was employed, 
and the MN array was mounted on the moving probe using double-sided adhesive tape. Prior to 
testing, the porcine skin samples were placed in waxed petri dishes. Continuous force and 
displacement measurements were recorded to identify the point of needle insertion. The speed of 
the moving probe was 0.01 mm s
-1
. 
Axial force mechanical testing of MNs 
To evaluate the mechanical behaviour of the 3D printed microneedles, fracture testing under 
axial loading was performed. The arrays were fixed onto a metal plate and were pressed against a 
flat metal block attached to the moving head of a Tinius Olsen testing machine, until a pre-set 
displacement of 500 μm (height/2) was reached. Continuous force and displacement 
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measurements were recorded to identify the point of needle failure. The speed of the moving 
probe was 1 mm/s and the experiments were replicated 5 times for each design. 
Preparation of porcine skin for in vitro release of insulin 
The release of insulin from the coated MNs through abdominal porcine skin was studied using 
Franz diffusion cells (PermeGear, Inc., PA, USA). The full thickness abdominal porcine skin 
was collected from a local slaughterhouse (Forge Farm Ltd, Kent, UK) and was then shaved 
using a razor blade. The fatty tissue below the abdominal area of porcine skin was removed with 
scalpel and then pinned onto polystyrene block and wiped with 70 % ethanol. The skin was then 
cut by applying the dermatome at an angle of ±45° (Padgett dermatome, Integra LifeTMSciences 
Corporation USA). The thickness of the skin was measured by using a calliper and the tissue 
disks of the required dimensions were cut for the Franz diffusion cells using a scalper. The skin 
tissue (1.0 ± 0.1 mm thick) was placed onto filter paper soaked in a small amount of saline 
phosphate buffer (pH 7.4) for 2 h.  
In vitro release of insulin through porcine skin 
A total diffusion area of 1.1 cm
2
 was used to assess the insulin release. The MN arrays were 
inserted into the abdominal porcine skin samples for 30 s, via manual finger pressure. The 
sample was then mounted onto the donor compartment of a Franz diffusion cell. The temperature 
of the Franz cells was maintained at 37ºC using an automated water bath (Thermo Fisher 
Scientific, Newington, USA). Sample fractions (6-6.5 mL h
-1
) were collected using an auto-
sampler (FC 204 fraction collector, Gilson, USA) attached to the Franz diffusion cells system. 
Statistical analysis for the drug release was performed by using a Mann-Whitney nonparametric 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
11 
 
test and t-test analysis for the in vivo studies (InStat, GraphPad Software Inc., San Diego, CA, 
USA), where samples were considered as statistically significant at p < 0.05. 
High-Performance Liquid Chromatography (HPLC) 
The amount of insulin collected from the receptor fluid was determined by HPLC (Agilent 
Technologies, 1200 series, Cheshire, UK) equipped with a Phenomenex Jupiter 5u c18 300 Å, 
LC Column (250×4.60 mm, particle size 5 μm, Macclesfield, UK). The mobile phase consisted 
of water with 0.1 % Trifluoroacetic Acid (TFA) and acetonitrile with 0.1% TFA (66:34v/v), with 
a 1 mL min
−1
 flow rate. The column was equilibrated at 35°C, the injection volume was 20 μL 
and the eluent was analysed with a UV detector at 214 nm. The results were integrated using 
Chemstation® software and the samples analysed in triplicates. 
In vivo release in diabetic mice 
Prior to the induction of diabetes, Swiss albino female mice (120 ± 10 g) were allowed free 
access to solid bottom cages with controlled diet and water for 3 days. Mice were subcutaneously 
injected on the flank with streptozotocin (70 mg kg
-1
) in citric acid buffer (pH 4.5) to produce a 
diabetic animal model. To confirm the induction of diabetes, the fasting blood glucose level was 
measured at scheduled times using a one-touch glucometer (ACCU-CheckVR Active, Roche, 
Germany). After one week, mice with blood glucose exceeding 300 mg/dl were considered as 
diabetic. The diabetic animals were anesthetised and shaved carefully using an electric razor 
(Panasonic, USA) 24 hours prior to the experiments. Furthermore, the diabetic mice were fasted 
for 12 hours before the beginning of the study, receiving only water and libitum. The mice were 
randomly divided into three groups (n=3 for each group): (1) untreated group as negative control; 
(2) subcutaneous injection (SC; 0.2 IU/animal) as positive control; (3) 3D printed MN (0.2 
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IU/array). The 3D printed MN arrays were applied onto the dorsal skin of the animals using 
adhesive tape (3M, USA) to prevent any dislodgement during therapy. After 2 hours, the 3D 
printed MN patches were removed. For all groups, blood samples were collected from the 
jugular vein at 0, 1, 2, 3 and 4 hours after the insulin administration and the blood glucose level 
was measured using the glucometer mentioned. Plasma insulin concentrations were measured via 
an insulin-EIA Test kit (Arbor Assays, MI, USA). The treatment strategy is described in Table 1. 
All animal experiments throughout this study were approved by the Research Ethics Committee 
(reference number 0003/17, Department of Pharmacy, Southern University Bangladesh) and 
conducted according to the Southern University Bangladesh policy for the protection of 
Vertebrate Animals used for Experimental and Other Scientific Purposes, with implementation 
of the principle of the 3Rs (replacement, reduction, refinement). No skin reactions to MNs 
occurred. 
Pharmacodynamic and pharmacokinetic profile of insulin-coated 3D printed MNs 
The minimum glucose level (Cmin) and the time point of minimum glucose level (Tmin) were 
calculated from the plasma glucose level versus time curve. The relative pharmacological 
availability (RPA) was calculated using equation 1.  
RPA(%) = (AAC3DMN×dosesc)/ (AACsc× dose3DMN) × 100                            (Eq.1) 
Where AAC3DMN indicates the area above the curve after the application of the insulin-coated 
3D printed MNs, and AACsc shows the area above the curve after the subcutaneous injection of 
insulin.  
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The maximum plasma insulin concentration (Cmax) and the time point of maximum plasma 
insulin concentration (Tmax) were calculated from the plasma insulin concentration (µIU/ml) 
versus time curve. The relative bioavailability (RBA) was determined using equation 2. 
RBA(%)=(AUC3DMN × dosesc)/ (AUCsc × dose3DMN) × 100                       (Eq.2) 
Where AUC3DMN indicates the area under the curve after the application of the insulin-coated 
3D printed MNs, and AUCsc shows the area under the curve after the subcutaneous injection of 
insulin. 
Results and Discussion 
Additive Manufacturing and printability of microneedles 
MN arrays featuring pyramid and spear needles were 3D printed using a commercial SLA printer 
based on digital CAD designs developed via appropriate engineering software. The polymer 
employed was a photo-sensitive Class I resin which has been FDA approved. All arrays were 
washed and subsequently cured under UV radiation in a controlled temperature environment to 
improve the material’s mechanical performance. 
The capability of 3D printing technology to manufacture complex structures reproducibly and 
accurately in a one-step-fashion, was exploited in this work to build different designs of MN 
arrays. Although the degree of complexity that can be achieved through 3D printing is often not 
achievable through many conventional techniques of MN manufacturing, the technology is 
hampered by restrictions in terms of resolution that can affect the formation of sharp MN tips. 
Conventional low-budget SLA printers have a maximum resolution of 100 microns that is 
governed by the size of the laser focal point and restricts the minimum size of MN tip that can be 
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formed. The MNs designed in the framework of this study featured a tip of 100 microns by 
design and their penetration capability through porcine skin was tested to verify that they will 
successfully and painlessly pierce the skin. 
The printability of MNs was further improved when printing-in-an-angle was implemented, 
leading to finer, sharper MN tips. An innate characteristic of the SLA technology is the 
interdependence between the print quality and the cross-sectional area in the z-axis; the smaller 
the z-axis cross-sectional area, the better the quality. This stems from the peel-off function of the 
printing process, according to which, after the completion of each layer, a wiper slides and peels 
the structure off the bottom of the resin tank. Larger z-axis cross sectional areas lead to greater 
forces applied by the wiper, which can deform the printed structures. Orienting the part to 
minimise the contact area of the structure to the resin tank avoids the possible distortions during 
the peel-off process and leads to better print quality.  
SLA parts are considered mechanically isotropic which ensures the mechanical properties of the 
arrays are not affected by the angle of printing. In addition, an influential factor of the 
mechanical performance of the MN arrays is the selection of post-process curing parameters 
(time and temperature). Further research is required to determine the effect of those factors on 
the overall mechanical and piercing behaviour of the MN arrays. In this work, the MNs were 
cured in a UV chamber for 60 min in temperature of 40 
o
C. It is demonstrated in this study that 
those parameters yielded systems that successfully pierced through porcine skin requiring small 
forces, with no needle failure occurring. 
As discussed above due to technical limitations of the existing MN manufacturing techniques 
(e.g. moulding, lithography) such as limited drug loading, dose consistency and scalability issues 
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there are no commercialized products. Polymeric MNs are fabricated using moulding approaches 
while metal MNs implement dip – coating techniques which renders both approaches impractical 
for large scale manufacturing. In contrast scale-up of SLA printed MNs is directly related to the 
usage of large volume printers or the in-line arrangement of existing printers.  We envisage that 
the implementation of SLA printed MNs will open new horizons for transdermal drug delivery 
due to the low cost of the printers, printing inks and fast fabrication times.  
SEM analysis demonstrated that through the use of the SLA technology, uniform and 
reproducible arrays were developed (Fig. 1a,b). In Fig. 1, the high consistency and 
reproducibility of the MN layers is depicted, and the formation of sharp tips is demonstrated. It is 
evident, that the high-resolution capabilities of the printer allowed the parallel fabrication of 
identical and reproducible arrays with characteristics that favour the skin insertion. 
Coating of microneedles through inkjet printing 
Insulin and sugar alcohol coatings were formed on the surface of the 3D printed MNs using 
inkjet printing and a piezoelectric dispenser. A similar process was developed in earlier studies 
for coating metallic MNs [16,27], where the applied voltage (mV) and pulse duration (ms) were 
tuned to achieve the production of droplets of 300 pL volume with particle size of 100-110 μm. 
Fig. 1c,d illustrates the uniformity and reproducibility of the coatings on the MN surface without 
any losses of material in the form of satellite droplets on the substrate. Moreover, it is 
demonstrated that the consecutive jetting cycles produced drug-containing films that are smooth 
and level in comparison to other techniques such as dip coating that may yield voluminous and 
inconsistent coatings. This smooth morphology of the films prevents the losses of drug during 
MN insertion that occur when bulky coatings remain on the skin surface. 
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The drug carriers selected were two alcohol sugars (xylitol, mannitol) and a disaccharide 
(trehalose). Those excipients have been reported to favour the immediate coating dissolution in 
the skin and to enhance insulin stability in solid state [28–30] . 
X-Ray Computer Micro Tomography 
The coated 3D printed pyramid MN arrays were scanned using the Bruker Skyscan 1172 and an 
overview of the array is presented in Fig. 2a. For sample A, an average needle base area of 1.095 
mm
2
 and an average needle height of 1.034 mm were measured. For samples B and C, the 
average needle base areas were measured as 1.065 mm
2
 and 1.091 mm
2
 and the average needle 
heights as 1.040 mm and 1.038 mm, respectively. The average interspacing of the pyramids 
between the centre points was 1.842 mm, 1.865 mm, and 1.864 mm between columns, and 1.788 
mm, 1.810 mm, and 1.796 mm between rows for samples A, B and C respectively. Scans taken 
from the left-hand side of the arrays illustrate the thin coating films fabricated through inkjet 
printing, in comparison with respective ones taken from the back side of the array (Fig. 2b,c). 
The relative density of the MNs relative to the control sample (uncoated 3D printed pyramid 
MNs) showed an increase of approximately 200 HU between all coated samples and the control 
(Fig. 3a,b). Profile lines across a row of MNs revealed a coffee-ring effect in the density of the 
coating material deposition. While denser material was distributed randomly within each of the 
MNs, a fringe layer of 10-15 μm was apparent with the effect being most pronounced in the 
insulin:xylitol coated sample (Fig. 3c).  
Penetration experiments in 8-ply strips of parafilm were performed applying a 5 N force (Fig. 4). 
The penetration depth was measured as 559 μm, 662 μm and 650 μm for samples A, B and C, 
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respectively. The μCT scans illustrate that the coating stays on the MN surface throughout the 
piercing process and there is no material remaining on the parafilm surface.  
Circular Dichroism 
Circular dichroism (CD) spectroscopy is a reliable technique for the evaluation of the secondary 
structure of proteins in a solution. The influence of the two polyols and the disaccharide on 
insulin molecule as well as their interactions were studied using CD and the estimation of insulin 
secondary structure was performed by CDSSTR method [31,32]. 
The far-UV CD spectra of insulin and insulin-sugar films (Fig. 5a) were found to be coincident 
with the one of standard insulin solution, showing double minima around 210 and 222 nm which 
are typical of predominant α-helix structure proteins as already reported elsewhere [28,33–35]. 
However, a slight decrease in Molar ellipticity is noted when insulin solution is dried which is 
also supported by the decrease of the estimated percentage of α-helix and increase of the β-sheet 
content. Such behaviour may be indicative of the unfolding tendency of insulin during 
dehydration [36]. Interestingly, once the sugars were added, all the respective insulin-sugar films 
spectra showed higher Molar intensities than the insulin film alone, indicating an increase in the 
α-helix content. The protective property of those sugars can be explained by the water 
replacement mechanism which proposes that sugars may maintain the three-dimensional 
structure of proteins by hydrogen-bonding with them [37,38] 
Among the tested sugars, xylitol presented the best capability to maintain insulin in its native 
secondary structure with even higher amounts of α-helix content. The reason for this still remains 
unclear and further research is needed. 
Raman Spectroscopy 
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In this work, the Raman spectrum of native insulin shows a strong peak at 1661 cm
-1
 due to the 
amide I mode of α-helix structure and a shoulder at 1682 cm-1 which is attributed to random coil 
form as previously reported by Yu et al. [40]. Distinctive peaks of sugars were not found in 
Raman mainly because insulin was 5 times more concentrated than the sugars in the films. 
Likewise, the amorphous nature of the dried formulation (XRD analysis - data not shown) is 
unlikely to afford a strong Raman signal.  
Overall, insulin-sugar formulations showed similar Raman spectra to the native insulin (Fig. 5b). 
Nonetheless, a slight shift in amide I band position can be seen for all formulations. Amide I 
band of insulin-xylitol and insulin-mannitol formulations was shifted towards greater frequency, 
1663 cm
-1
 and 1662 cm
-1
, respectively, while insulin-trehalose band was shifted to lower 
frequency at 1658 cm
-1
. Those events were also reported by Carpenter and Crowe [37] and 
Souillac et al. [41], who described that those changes might be due to the different effect of each 
sugar on the vibrational spectra of insulin as well on the hydrogen bonding and couplings 
between the adjacent peptide units.  
Many researchers have investigated the protective properties of different sugars on polypeptides, 
proteins and biomolecules [42–44]. It has been advocated that protein aggregation and 
denaturation can be prevented by using carbohydrates as protectants. Protein protection by the 
sugars in a dried system can be explained by the water replacement mechanism which suggest 
the sugars may substitute water molecules around the biomolecules of proteins, maintaining its 
three-dimensional structure by providing sites with hydrogen-bonding species [37,45,46].   
Zeng et al. studied the impact of relative humidity (RH) on dehydration of insulin crystals and 
they found the hydration water from insulin crystal can be gradually excluded when the RH is 
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decreased. They used the high frequency region in Raman spectroscopy to access the band at 
~3450cm
-1
 which is caused by both water and amino acid residues with O-H groups. A 
continuous dropping of the O-H stretching band around 3450 cm
-1
 was observed while the RH 
was reduced, indicating dehydration of the molecule [47]. 
From Fig. 5b it can be seen that for all formulation the S-S vibration bands are located close to 
513 cm
-1
 suggesting that all disulphide bonds are in an adopted more stable gauche – gauche - 
gauche conformation [47,48] as a result of the complete water removal during inkjet printing. 
Tyr residues present Raman peaks at 642, 828, 852, and 1174 cm
−1
, while the 1206 cm
−1
 peak is 
related to both Tyr and Phe residues. Furthermore, the ratios of I852/I828 and I1174/I1206 varied from 
0.91 – 1.02 and 0.77 – 0.81 respectively.  These values are much lower compared to those 
observed from Zeng et al. [47], for insulin crystals at very low RH (2%). This phenomenon 
suggests significant water loss of the coated formulation and stronger H – bonding interactions.  
Vibrational modes in the area of 1100 – 1300 cm-1 have shown to be sensitive to the changes of 
hydrogen bonds which involve the phenolic hydroxyl groups of Tyr residues and particularly the 
7á frequency. In Fig. 5b the 7á has a frequency of 1275cm
-1
 which is a robust evidence that the 
phenolic OH group of Tyr is strongly hydrogen bonded to a base atom [49].  
Penetration studies through porcine skin 
The 3D printed pyramid and spear shaped MN arrays were tested for their porcine skin 
penetration capability using a texture analyser. Identical experiments were performed using 
metallic MNs and the results were compared to the respective ones obtained from the 3D printed 
MN experiments. All piercing tests were successful with no MN damage or failure. Throughout 
each test, measurements of force and displacement were taken (Fig. 6a). 
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All curves presented an initial linear segment (displacement < 0.3 mm); after that, the slope was 
changing constantly until a maximum force value was reached and a steep decrease of the force 
was observed. This value is identified as the maximum force required for MN insertion [26]. The 
non-linear behaviour of the force-displacement curve indicates that the process of MN insertion 
to the skin is comprised of small penetrations where the MNs gradually tear the skin, before the 
load reaches the maximum value that makes the insertion abrupt [50]. The maximum force 
required for the MNs to successfully pierce the skin plays a crucial role when different MN 
designs need to be compared. As presented in Fig. 6b, the pyramid MN required the least amount 
of force to penetrate the porcine skin. 
Axial force mechanical testing of MNs 
The two studied MN designs were tested under compressive axial loading to determine the force 
of microneedle fracture as a function of geometry. The force vs displacement measurements and 
respective fracture strength values are presented in Fig. 7.   
The two designs exhibited different mechanical behaviours during testing. For both designs, the 
recorded force increased until the ultimate load was reached, and fracture occurred. For the spear 
MNs, the point of fracture appears as a peak at approximately 175 N, followed by a drop of the 
recorded load; as the MNs were kept being pressed against the metal block after fracture, the 
load was considerably decreased. On the contrary, the pyramid geometry showed a discontinuity 
at approximately 457 N which is identified as the point of initial needle failure. Afterwards, the 
load kept increasing as the microneedles kept being compressed. This difference in mechanical 
behaviour is attributed to the different modes of needle failure. On the one hand, the spear MNs 
fractured in the lateral direction, perpendicular to the loading axis, a finding that was confirmed 
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by visual observation. This mode of failure was expected, due to the small thickness of the MNs 
in that direction, which translates to minimisation of area, thus increased stress fields. On the 
other hand, the pyramid MNs failed under pure compression, with the tip failing first and 
additional, increasing force required for the compression of the remaining MN body. These 
findings verify that both designs are safe for application since the fracture strengths of the arrays 
are far greater than the respective forces needed for needle penetration through porcine skin. 
They also confirm that the pyramid geometries present the best potential between the two studied 
designs. 
In vitro release of insulin through porcine skin 
The in vitro insulin release studies from 3D printed pyramid and spear MNs were investigated 
using porcine skin in Franz cells. The used carriers, mannitol, trehalose and xylitol not only 
preserved insulin in its native form but also provided fast dissolution rates.  As shown in Fig. 
8a,b for the pyramid designs approximately 80% of insulin was released in the first 2 min with 
86 – 92% within 8 min. The rapid release profiles were obtained for all insulin carriers and no 
statistical difference was observed (two-tail p = 0.0021).   
The coating of each pyramid side resulted to higher surface area exposed for hydration and thus 
faster hydration rates. In contrast, the spear 3D printed designs presented slightly slower insulin 
release rates with 62 – 70% and 81 – 84% released within 2 min and 8min respectively. Overall, 
the rapid insulin release rates of the 3D printed MNs was attributed to the hydrophilic nature of 
the three carriers and the thin coating layers (10 – 15μm) as shown from the μCT analysis. 
In vivo transdermal delivery of insulin in diabetic mice 
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Diabetes was successfully induced in mice after 7 days of streptozotocin administration. The 
preliminary diabetes (hyperglycemia) was demonstrated as 340 ± 10 mg/dl. The diabetic mice 
were divided into three groups: Untreated (negative control), subcutaneously (SC) injected 
(positive control) and treated with the 3D printed insulin-coated MNs. Fig. 9 shows the 
application process of the 3D printed MN arrays. 
The dose 0.2 IU/array was selected in order to avoid hypoglycaemia in mice for 4 h. The 
comparative studies on different delivery strategies in plasma glucose levels are shown in Fig. 
10a. Insulin-coated 3D printed MN arrays showed a remarkable steady state hypoglycaemia 
effect (32.8% from total value) in comparison to negative and positive control. After an hour, 
subcutaneous injection (0.2 IU/injection) facilitated a rapid increase in insulin concentration in 
blood and hence the decrease in plasma glucose level was approximately 30.1% from its primary 
value. A comparable blood glucose regulation was observed between the SC group and the MN 
group which was achieved within 1 h [51]. Interestingly, the 3D printed patch presented the same 
rate to reach its lowest glucose level compared to the SC injection. In similar study 
biodegradable MN patches Tmin of glucose levels was achieved within 2 h with administrated 
doses of 5 – 10 IU per patch [13]. The main reason for the faster glucose rates is that in Zhang et 
al.  (2018) insulin was encapsulated in moulded MN patches while for the 3D printed patches is 
applied on the microneedle surface with very hydrophilic thin layers resulting in rapid insulin 
release. Moreover, previous studies have shown that microneedle injection of insulin to human 
diabetic subjects was chosen over hypodermic infusion and that pharmacokinetics were faster 
when insulin was administered to the skin compared to the subcutaneous injections [52]. 
Although the plasma glucose level versus time profile was similar to previous findings [53–57] 
the steady state plasma glucose level was maintained up to 4 h while the untreated group 
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(negative control) remained unchanged (no hypoglycaemia) for the same period. These findings 
suggest that insulin is being released from the 3D printed MNs to the mice blood stream via 
passive diffusion to blood capillary.  
Fig. 10b illustrates the plasma insulin concentration versus time where both SC and 3D printed 
MN groups achieved the highest amount of plasma insulin concentration after 1 h of 
administration. The control group did not show any detectable plasma insulin concentration. The 
highest insulin level of the 3D printed MNs is slightly lower to the SC injection but no statistical 
difference was observed. As shown in Fig. 10b after post – administration for 4 h the serum 
insulin of 3D printed microneedles was higher to the SC injection.  
Tables 2 and 3 represent the pharmacodynamic parameters of plasma glucose levels and the 
pharmacokinetic parameters for plasma insulin concentrations, respectively. The RPA and RBA 
for the insulin-coated 3D printed MNs group were both about 85-96%. These results indicate that 
insulin released from 3D printed MNs was almost completely absorbed from the skin into the 
systemic circulation, and the pharmacological activity of the released insulin remained intact 
after the delivery with the 3D printed MNs. 
Conclusions 
MN arrays of high quality and reproducibility, featuring spear and pyramid-shaped needle 
geometries, were successfully fabricated by a biocompatible resin using stereolithography. The 
3D printed polymeric MNs required low forces to penetrate porcine skin, in comparison with 
metallic MNs. Uniform and accurate insulin-sugar thin layers were applied on the surface of the 
MNs through inkjet printing, with no satellite droplets detected on the substrate. The insulin 
integrity was found to be preserved by all carriers, namely the α–helix and β-Sheet, with xylitol 
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showing the optimum performance. In vivo animal trials demonstrated that 3D printed MNs 
facilitate rapid low glucose levels with longer duration compared to SC injections.  
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FIGURES 
 
Figure 1. SEM images of the 3D printed MNs. (a) Uncoated pyramid; (b) uncoated spear; (c) 
coated pyramid; (d) coated spear. The thin coating films on the MNs were created using an inkjet 
printer. The formulations employed for the coatings contained insulin and a sugar used as a 
carrier (xylitol, mannitol and trehalose) in a 5:1 ratio. Each MN patch was coated with 10 IU. All 
insulin-carrier combinations formed coatings with similar morphology. The carrier used for 
captions (c) and (d) is xylitol.  
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Figure 2. μCT images of the pyramid MN arrays coated with insulin:xylitol formulation. 
(a) Overview; (b) image taken from the back side; (c) image taken from the left-hand side of the 
array, showing the thin film coating. 
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Figure 3. μCT evaluation. (a) Profile lines, measured across a single row of the control sample 
(uncoated array) and (b) the coated pyramid MN array with insulin:xylitol formulation, showing 
a 200 HU increase; (c) cross-section of the coated MN array showing a fringe layer of 10-15 μm.  
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Figure 4. Cross section of MN array penetration through 8-ply strip of parafilm, applying a 5N 
load. 
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Figure 5. a) CD of insulin and insulin formulations and b) Raman spectra from 500 to 1800 cm
-1
 
of pure insulin and insulin-sugars. 
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Figure 6. Penetration studies of MNs through porcine skin, comparing 3D printed spear and 
pyramid designs with metallic MNs. (a) Force against displacement curves recorded during MN 
insertion tests; (b) Maximum force required for MN penetration. 
 
Figure 7. MN fracture testing for pyramid and spear designs. (a) Force against displacement 
curves recorded during MN fracture tests; (b) Fracture MN strength 
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Figure 8. In vitro insulin release through porcine skin from a) the pyramid and b) the spear MN 
designs for all investigated drug carriers. 
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 Figure 9. Experimental mice (A) before the application, (B) during the application and (C) after 
removal of the 3D printed MN array for the delivery of insulin to diabetic mice. 
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Figure 10. a) Comparative plasma glucose level vs time for untreated group, subcutaneous (SC) 
injection and insulin-coated 3D Printed MN array applied to diabetic mice, over 4 hours (n=3), 
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b) comparative plasma insulin concentration vs time for untreated group, subcutaneous (SC) 
injection and insulin-coated 3D Printed MN array applied to diabetic mice, over 4 hours (n=3).  
 
TABLES 
Table 1 Treatment protocol for insulin-coated 3D printed MN array.  
Day Stage Treatment strategy  
-7 Animal model selection 
and isolation  
Transfer mice to study isolator 
0 Induction of diabetes  Weigh animals and injected with streptozotocin 
(diabetes inducer) 
 Daily blood glucose measurements 
1  
 
Observation 
 
 
 
Blood glucose level measurements 
2 
3 
4 
5 
6 
7 Confirmation of 
diabetes induction 
Blood glucose level exceeds 300 mg/dl within 7 days.  
8 Antidiabetic therapy 
using insulin-coated 3D 
printed MN array 
After treatment, hourly (up to 4 hours) blood samples 
were collected from the jugular vein and the blood 
glucose level was measured. 
The study was conducted for 24 hours. 
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Table 2. Pharmacodynamic parameters for plasma glucose levels of diabetic mice for untreated 
groups, subcutaneous (SC) injection (insulin dose: 0.2 IU) and 3D Printed MN array (insulin 
dose: 0.2 IU) (n=3).  
Group Cmin (%) Tmin (h) AAC0 to 4 (% hr) RPA (%) 
Untreated groups 89.5 ± 4.2 3 22.7 ± 1.2 - 
SC injections 32.8 ± 3.7 1 208.5± 3.7 100 
3D Printed MN arrays 30.1 ± 1.0 1 240.6 ± 2.9 122 
Cmin, minimum glucose level; Tmin, time point of minimum glucose level; AAC0 to 4, area above 
the plasma glucose concentration vs. time curve; RPA, relative pharmacological availability 
compared to subcutaneous injection.  
 
Table 3. Pharmacokinetic parameters for plasma glucose levels of diabetic mice for untreated 
groups, subcutaneous (SC) injection (insulin dose: 0.2 IU) and 3D Printed MN array (insulin 
dose: 0.2 IU) (n=3).    
Group Cmax (µIU ml
-1
) Tmax (h) AUC0 to 4 (µIUhr
-1
 ml
-1
) RBA (%) 
Untreated groups 0 0 0 0 
SC injections 63.2 ± 8.8 1 120.5 ± 6.4 100 
3D Printed MN arrays 59.9 ± 7.9 1 147.4 ± 5.8 115 
Cmax, maximum plasma insulin concentration; Tmax, time point of maximum plasma insulin 
concentration; AUC0 to 4, area under the plasma insulin concentration vs. time curve; RBA, 
relative bioavailability compared with subcutaneous injection. 
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Highlights 
 Fabrication of 3D printed novel microneedle arrays via stereolithgraphy using a biocompatible 
resin 
 Design of microneedle arrays for drug delivery through the skin 
 Use of inkjet printing technology to deposit insulin on 3D printed microneedles for rapid release 
 The printability and skin piercing capacity of 3D printed MNs is discussed 
 In vivo pre-clinical trials demonstrated excellent hypoglycaemia control 
ACCEPTED MANUSCRIPT
